Loading…
Prebiotic capacity of novel bioengineered wheat arabinoxylans in a batch culture model of the human gut microbiota
Arabinoxylan (AX) is an essential component of dietary fiber with potential prebiotic properties. However, owing to its complex structure, fermentation of AX by gut microbes is structure dependent. In this study, we evaluated the effect of bioengineered wheat AX on the metabolism and composition of...
Saved in:
Published in: | Frontiers in microbiomes 2023-06, Vol.2 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Arabinoxylan (AX) is an essential component of dietary fiber with potential prebiotic properties. However, owing to its complex structure, fermentation of AX by gut microbes is structure dependent. In this study, we evaluated the effect of bioengineered wheat AX on the metabolism and composition of gut microbiota using an
in vitro
fermentation model. We compared the effect of bioengineered AX with that of untreated AX and a control. Structurally modified AX did not significantly alter gut microbiome composition within 48 h of treatment; however, it enhanced the abundance of health-promoting bacterial taxa, such as
Bacteroides
,
Bifidobacterium
,
Anaerofustis
, and
Eubacterium.
Furthermore, the bioengineered AX significantly increased the level of acetate produced over 24 h. The amount of microbiota-generated butyrate was significantly increased 24 h after adding α-L-arabinofuranosidase-treated AX. AX treated with the α-L-arabinofuranosidase B25 enzyme induced higher levels of production of total short-chain fatty acids by the microbiota from four donors. The results of this study provide evidence that enzymatic structural modification of AX has the potential to modulate gut microbiome composition and metabolic activities. |
---|---|
ISSN: | 2813-4338 2813-4338 |
DOI: | 10.3389/frmbi.2023.1156797 |